Table 3.
Changes in obesity-related items and quality of life during COVID-19 LD
| Before LD (n = 51) | After LD (n = 51) | p Value | |
|---|---|---|---|
| BMI (Kg/m2) | 42.7 (± 10) | 43.2 (± 11) | < 0.001* |
| Following any weight-loss program | 23 (45%) | 10 (20%) | < 0.001* |
| Number of drugs used | 6.1 (± 4) | 6.1 (± 4) | 1 |
| OSS | |||
| - BMI | 0.86 (± 0.9) | 0.88 (± 0.9) | 0.6 |
| - Obesity-related comorbidities | 1.68 (± 1.1) | 1.70 (± 1.1) | 0.3 |
| - Obesity-related socio-labor impact | 0.30 (± 0.5) | 0.42 (± 0.6) | 0.014* |
| - Total score | 2.84 (± 1.7) | 3.00 (± 1.8) | 0.011* |
| EQ-5D | |||
| - Mobility | 1.29 (± 0.5) | 1.31 (± 0.5) | 0.6 |
| - Self-care | 1.2 (± 0.4) | 1.2 (± 0.4) | 1 |
| - Usual activities | 1.2 (± 0.4) | 1.2 (± 0.4) | 1 |
| - Pain/discomfort | 1.5 (± 0.6) | 1.4 (± 0.6) | 0.2 |
| - Anxiety/depression | 1.2 (± 0.5) | 1.5 (± 0.7) | 0.001* |
| - Self-rated health index | 69 (± 1.8) | 64 (± 1.8) | < 0.001* |
Data is shown as mean (± standard deviation) or n (percentage)
LD lockdown, BMI body mass index, OSS Obesity Surgery Score, EQ-5D EuroQol group quality of life validated questionnaire. *Statistically significant differences